Advancements in Bladder Cancer

1 hour video discussion focusing on case studies in bladder cancer


Acknowledgements

Support provided by independent educational grants from:

  • Astellas and Pfizer, Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck & Co., Inc.

Target Audience

  • JUA Young Urologists

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Discuss risk stratification of patients with NMIBC, including important features and available stratification tools, as well as management strategies based on assigned risk
  2. Characterize available treatments for patients with BCG unresponsive NMIBC
  3. Discuss guideline-based management options for patients with non-metastatic, muscle invasive bladder cancer
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
02/26/2024
Course expires: 
03/09/2027
Rating: 
0

Pre-test

Welcome and Introductions

Segment 1: Risk Stratification

Segment 2: BCG-unresponsive Bladder Cancer

Segment 3: Current best practices for non-metastatic MIBC

Wrap-up

Post-test

Faculty Disclosures

NameCompany NameRelationship TypeEnd Date
Nishiyama, HiroyukiMerck Sharp & Dohme (MSD)Meeting Participant or LecturerCurrent
Nishiyama, HiroyukiAstellasMeeting Participant or LecturerCurrent
Nishiyama, HiroyukiAstraZenecaMeeting Participant or LecturerCurrent
Nishiyama, HiroyukiNippon Kayaku Co.LtdMeeting Participant or LecturerCurrent
Nishiyama, HiroyukiOno PharmaceuticalMeeting Participant or LecturerCurrent
Nishiyama, HiroyukiBristol Myers Squibb (BMS)Meeting Participant or LecturerCurrent
Nishiyama, HiroyukiMerck Biopharma Co.Ltd.Meeting Participant or LecturerCurrent
Nishiyama, HiroyukiChugai PharmaOther-Contract researchCurrent
Nishiyama, HiroyukiOno PharmaceuticalConsultant or AdvisorCurrent
Nishiyama, HiroyukiAstraZenecaConsultant or AdvisorCurrent
Nishiyama, HiroyukiMerck Sharp & Dohme (MSD)Consultant or AdvisorCurrent
Nishiyama, HiroyukiJanssen.comConsultant or AdvisorCurrent
Porten, Sima PrabodhPhotocureScientific Study or TrialCurrent
Porten, Sima PrabodhStrykerConsultant or AdvisorCurrent
Porten, Sima PrabodhAstraZenecaConsultant or AdvisorCurrent
Porten, Sima PrabodhPacific EdgeConsultant or AdvisorCurrent
Scarpato, Kristen R.CxBladderScientific Study or TrialCurrent

Education Council Disclosures

PDF iconEducation Council Disclosures_2024_01_25_2.pdf

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pre-test, viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Release Date: February, 2024
Expiration Date: March 09, 2027

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.